OncoPharm

By John Bossaer

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodical... more

· Science

4.9

179179 ratings

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about OncoPharm:

How many episodes does OncoPharm have?

The podcast currently has 375 episodes available.

OncoPharm episodes:

June 08, 2023 ASCO '23 Appetizers
ASCO '23 Appetizers by John Bossaer
...more
12min
June 01, 2023 PROpel and Cilostazol to Prevent Paclitaxel Neuropathy
Olaparib + Abiraterone is FDA approved for mutated-BRCA prostate cancers. Olaparib has a bit of convoluted story to unpack in this patient population.
Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol?
PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043
Cilostazol RCT: https://doi.org/10.1002/phar.2830
Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514
...more
18min
May 25, 2023 Epcoritamab
We discuss the newly approved CD20-CD3 T-cell engager for subcutaneous (SC) administration to treat DLBLC after 2 or more lines of therapy.
...more
16min
May 18, 2023 Trimodality Treatment For Bladder Cancer
A recent paper serves as a good prompt to discuss trimodality treatment for muscle-invasive bladder cancer and the data supporting its use.
Zlotta et al: https://doi.org/10.1016/S1470-2045(23)00170-5
...more
17min
May 11, 2023 GAIA-CLL13 & COSMIC-313
Today's Pod discusses...
1) A large trial comparing 4 different CLL treatments
GAIA-CLL13: https://www.nejm.org/doi/full/10.1056/NEJMoa2213093
2)Adding Cabozantinib + Nivo/Ipo vs. Nivo/Ipi in intermediate/poor risk mRCC
COSMIC-313: https://www.nejm.org/doi/full/10.1056/NEJMoa2212851
3) A potential future biomarker for predicting response to PD-(L)1 targeted therapies
Functional PD-1/PD-L1 Engagement: https://pubmed.ncbi.nlm.nih.gov/?term=36821809
...more
23min
May 04, 2023 SUNLIGHT
Talking 3rd-line treatment of metastatic colon cancer. Tipiracil-trifluridine + bevacizuamb vs. tipiracil-trifluridine alone. And a bit on the theory of "bevacizumab beyond progression."
SUNLIGHT: https://www.nejm.org/doi/full/10.1056/NEJMoa2214963
...more
14min
April 27, 2023 QuANTUM First (Quizartinib 1st Line in AML)
Quizartinib vs. Placebo(?) + Chemo in newly diagnosed AML.
We add a bit of context about quizartinib's history leading up to this study preview possible role in therapy if approved in the future.
Link: https://doi.org/10.1016/S0140-6736(23)00464-6
...more
19min
April 20, 2023 ICI + Bacterial Supplementation
We take a peak at an intriguing study (n = 29) that gave some metastatic RCC patients receiving nivolumab + ipilimumab a supplement of a bacterium (n = 19) and a control group.
We discuss what to look for in the future studies that are likely to follow with similar methods.
...more
13min
April 13, 2023 Neoadjuvant Chemo In Breast Cancer
The Landmarks of OncoPharm series returns to discuss NSABP's B18 story of neoadjuvant vs. adjuvant AC in stages I & II breast cancer from 1998.
B18: https://pubmed.ncbi.nlm.nih.gov/?term=36989610
Flashback Flashforeward: https://pubmed.ncbi.nlm.nih.gov/?term=36989608
...more
13min
April 06, 2023 Olanzapine & Pembrolizumab (endometrial, urothelial) Updates
Lots of updates:
Olanzapine increases weight gain, QOL in some advanced cancer: https://pubmed.ncbi.nlm.nih.gov/?term=36977285
Chemotherapy Toxicity - When Less is More: https://www.nejm.org/doi/full/10.1056/NEJMcibr1202395
Pembro + Chemo improves PFS > chemo alone in advanced endometrial cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2302312
Enfortumab vedotin + pembrolizumab gets an accelerated approval for cisplatin-ineligible patients with urothelial carcinoma. Safety signals seen.
...more
21min

FAQs about OncoPharm:

How many episodes does OncoPharm have?

The podcast currently has 375 episodes available.

More shows like OncoPharm

JAMA Editors' Summary by JAMA Network

JAMA Editors' Summary

127 Listeners

NEJM This Week by NEJM Group

NEJM This Week

314 Listeners

JAMA Clinical Reviews by JAMA Network

JAMA Clinical Reviews

478 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,324 Listeners

Up First from NPR by NPR

Up First from NPR

56,155 Listeners

Core IM | Internal Medicine Podcast by Core IM Team

Core IM | Internal Medicine Podcast

1,085 Listeners

The ONS Podcast by Oncology Nursing Society

The ONS Podcast

196 Listeners

ASCO Guidelines by American Society of Clinical Oncology (ASCO)

ASCO Guidelines

44 Listeners

Real Life Pharmacology - Pharmacology Education for Health Care Professionals by Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist

Real Life Pharmacology - Pharmacology Education for Health Care Professionals

694 Listeners

OncLive® On Air by OncLive® On Air

OncLive® On Air

21 Listeners

Harrison's PodClass: Internal Medicine Cases and Board Prep by AccessMedicine

Harrison's PodClass: Internal Medicine Cases and Board Prep

318 Listeners

The Curious Clinicians by The Curious Clinicians

The Curious Clinicians

364 Listeners

WolverHeme Happy Hour by Bernard Marini, Anthony Perissinotti, et al.

WolverHeme Happy Hour

28 Listeners

Two Onc Docs by Sam and Karine

Two Onc Docs

165 Listeners

Oncology Brothers: Practice-Changing Cancer Discussions by Oncology Brothers

Oncology Brothers: Practice-Changing Cancer Discussions

37 Listeners